Journal
LUNG CANCER
Volume 115, Issue -, Pages 84-88Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.11.017
Keywords
Immune-checkpoint inhibitors; PD-L1; NSCLC; Meta-analysis
Categories
Ask authors/readers for more resources
Introduction: Role of PD-L1 expression to guide immunotherapies in previously treated advanced NSCLC remains unclear and there is a lack of data comparing immune checkpoint inhibitors (ICIs) with each other. This network meta-analysis (NMA) aims to compare survival with las to docetaxel and perform indirect comparisons between ICIs in the PD-L1 unselected population and by PD-L1 expression levels. Methods: PubMed was searched and study screening was performed by two independent reviewers. NMA of survival outcomes in the PD-Ll unselected population and by PD-L1 expression levels < 1%, > = 1%, > = 5%, > = 10%, and > = 50% was performed. Head-to-head indirect comparisons were constructed and treatment rankings were provided. Potential survival benefits by PD-L1 expression level as compared to a PD-L1 unselected population were estimated. Results: 5 trials with 3024 total patients were included for meta-analysis. Overall, ICIs improved survival across PD-L1 expression levels compared to docetaxel, although there was only weak evidence of benefit for individual ICI nivolumab or atezolizumab in PD-L1 < 1%. PD-Ll subgroups suggested positive dose-response relationship between PD-L1 expression levels with survival benefits. In addition, there were also survival benefits due to selecting for PD-L1 in the PD-L1 > = 10% and > = 50% subgroups as compared to the PD-L1 unselected population. Indirect comparisons of ICIs showed little evidence of differences between nivolumab, pembrolizumab and atezolizumab. Discussion: ICIs improve survival in previously treated advanced NSCLC patients across PD-L1 expression levels compared to docetaxel. There is a positive dose-response relationship between PD-L1 expression and survival benefits, and little evidence of survival differences between nivolumab, pembrolizumab and atezolizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available